Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis
Published: 13 Jun 2020
Views: 120
Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany
Dr Simon Renders speaks to ecancer about the study he presented during the presidential symposium at the EHA 2020 virtual meeting.
He summarises the background of the study, which identified netrin-1 as a regulator of haematopoietic stem cell dormancy and function through its receptor, neogenin.
Dr Renders also explains the implications this pathway could have for stem cell ageing, along with the methods used for this study.
Related Videos
New CAR T therapy for relapsed and refractory ALL
Dr Claire Roddie - University College London, London, UK
25 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
16 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
Managing Hodgkin lymphoma during the COVID-19 outbreak
Dr Anna Sureda - Hospitalet de Llobregat, Barcelona, Spain
20 Apr 2020
What is the role of autologous stem cell transplant in multiple myeloma?
Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical ...
25 Sep 2019
Using bioinformatics and genomics to treat AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
20 Jun 2019
The changing landscape of AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
20 Jun 2019
Multiple myeloma highlights and more from ASH 2018
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
3 Dec 2018
Myeloma XI study: Quadruplet regimen for transplant eligible patients
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
3 Dec 2018
